You are here: Industry Insights > Avastin

News List

Innovent Out-Licenses Commercial Rights for Avastin® Biosimilar to Coherus BioSciences in the United States and Canada prnasia
January 15, 2020
Coherus plans to file a Biologics License Application ("BLA") with the U.S. Food and Drug Administration ("FDA") in late 2020 or early 2021 depending on FDA interaction timing, and to launch directly upon approval.
Coherus signs in-licensing agreement for Avastin biosimilar pharmaceutical-technology
January 15, 2020
Coherus BioSciences has signed an in-licensing agreement to acquire commercial rights of Innovent Biologics’ biosimilar candidate to Avastin (bevacizumab) (IBI305) in the US and Canada.
Samsung Bioepis, 3SBio partner to expand biosimilar business in China biospectrumasia
January 07, 2019
Samsung Bioepis Co., Ltd. has announced that its rapidly growing biosimilar business will expand into mainland China through a licensing agreement with 3SBio Inc.
Pfizer’s cut-price version of Avastin wins EU panel greenlight expressbpd
December 18, 2018
Pfizer’s Zirabev is a cheaper version to Roche Holding’s leading cancer drug Avastin
Italy free to reimburse off-label Avastin, rules EU court pharmaphorum
November 28, 2018
Novartis and Roche’s long-running battle to try to prevent off-label prescribing of Roche’s Avastin in place of their approved Lucentis product for the eye disease age-related macular degeneration (AMD) has been dealt a blow by the European Court of Justi
High Court rejects Novartis, Bayer’s bid to outlaw off-label Avastin pharmatimes
September 27, 2018
Bayer and Novartis have lost a landmark case in the UK seeking to prevent the off-label use of Roche’s Avastin to treat wet AMD...
English court backs NHS in fight with Bayer, Novartis over off-label Avastin use fiercepharma
September 25, 2018
After a long legal fight with Bayer and Novartis, England’s National Health Service has won the right to use a compounded form of Roche’s Avastin off-label in patients with wet age-related macular degeneration over much ...
Avastin wins full green light for glioblastoma pharmatimes
December 08, 2017
Roche group Genentech has announced full US approval for Avastin for the treatment of adults with glioblastoma that progressed following prior therapy.
US FDA approves Genentech’s Avastin for glioblastoma pharmaceutical-technology
December 08, 2017
The US Food and Drug Administration (FDA) has provided full approval for Genentech’s Avastin (bevacizumab) to treat adults with glioblastoma that progressed after previous therapy.
FDA considers Avastin as first-line ovarian cancer therapy pharmatimes
October 30, 2017
US regulators are reviewing a potential new indication for Avastin as a first-line option for advanced ovarian cancer, filed by Roche group Genentech.

Previous page 1 2 3 Next page